Gilead’s ‘Truvada’ positioned at top in domestic HIV treatment market

The Gilead Sciences’ HIV therapy, Truvada, was observed to maintain the top position in the domestic HIV market.

According to the IMS Health DATA on the 8^th, the Truvada backbone treatment’s market share in the domestic HIV market was 59.0% increased approximately by 9.1%, becoming the top in the market.

It was estimated Truvada was able to grow because STR Stribild’s prescriptions were inc...